2024 ACR guidelines on screening, treatment, and management of patients with lupus nephritis
https://doi.org/10.14412/1996-7012-2025-3-27-32
Abstract
This article presents the current guidelines of the American College of Rheumatology (ACR) on the screening, treatment, and management of patients with lupus nephritis (LN), accompanied by comments from Russian experts. The discussion includes indications for renal biopsy, a new approach to the treatment of various classes of LN using triple and dual immunosuppressive therapy, as well as recommended glucocorticoid dosages and treatment durations.
About the Authors
E. A. Aseeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Elena Alexandrovna Aseeva
34A, Kashirskoye Shosse, Moscow, 115522
S. K. Soloviev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoye Shosse, Moscow, 115522
E. A. Pletnev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoye Shosse, Moscow, 115522
A. V. Dacina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoye Shosse, Moscow, 115522
References
1. Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: history and modernity. Nauchno-prakticheskaya revmatologiya. 2022;60(4):397-412. (In Russ.).
2. Faurschou M, Dreyer L, Kamper AL, et al. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010 Jun;62(6): 873-80. doi: 10.1002/acr.20116.
3. Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol. 2009 Jan;36(1):63-7. doi: 10.3899/jrheum.080625.
4. Mahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression. Lupus. 2020 Aug; 29(9):1011-1020. doi: 10.1177/0961203320932219. Epub 2020 Jun 22.
5. Mok CC, Kwok RC, Yip PS. Effect of renal disease on the stand-ardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013 Aug;65(8):2154-60. doi: 10.1002/art.38006.
6. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 Aug;54(8):2550-7. doi: 10.1002/art.21955.
7. Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020 Feb 18;7(1): e000389. doi: 10.1136/lupus-2020-000389. eCollection 2020.
8. American College of rheumatology. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. https://rheumatology.org/lupus-guideline/
9. Solov'ev SK, Kozlovskaya NL, Aseeva EA et al. Lupus nephritis – modern aspects of diagnosis and therapy. Part I. Nauchno-prakticheskaya revmatologiya. 2024;62(1):55-64. (In Russ.).
10. Rovin BH, Ayoub IM, Chan TM, et al. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024 Jan;105(1S):S1-S69. doi: 10.1016/j.kint.2023.09.002.
11. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus highdose intravenous cyclophosphamide. Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461.
12. Aseeva EA, Solov'ev SK, Kozlovskaya NL, et al. Lupus nephritis. Part II, modern ideas about therapy. Nauchno-Prakticheskaya Revmatologia. 2024;62(4):377-384 (In Russ.).
13. Furie RA, Rovin BH, Garg JP, et al; REGENCY Trial Investigators. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N Engl J Med. 2025 Apr 17;392(15): 1471-1483. doi: 10.1056/NEJMoa2410965. Epub 2025 Feb 7.
Review
For citations:
Aseeva EA, Soloviev SK, Pletnev EA, Dacina AV. 2024 ACR guidelines on screening, treatment, and management of patients with lupus nephritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(3):27-32. (In Russ.) https://doi.org/10.14412/1996-7012-2025-3-27-32
Views:
346
Email this article 